

Boston Common Asset Management is delighted to announce that it is the first U.S. asset manager signatory to the Access to Medicines (AtM) Investor Statement which has 19 institutional investor signatories representing over \$2 trillion in assets (as of December 2008). Please see link to statement http://www.atmindex.org/about/institutional_investors

Since 2007, Boston Common Asset Management has been providing input to the AtM Index's methodology to develop a relative ranking of the top global pharmaceutical companies on their performance related to access to medicines. In June 2009, we participated in the AtM Index's U.S. roundtable to consult on the 2008 methodology with other global health experts. Access to medicines has become an increasingly important issue for pharmaceutical companies to address as part of their core business strategy, especially because they are looking to emerging markets for growth opportunities. In our view, access to medicines is a key element to sustainable business models in emerging markets. Boston Common joins as the latest signatory and commends the advances that the Access to Medicines Index has taken to strengthen the 2010 methodology to move from analyzing companies' policies to performance on the ground and expanding the geographic focus and disease burden.

Boston Common will continue to use the Access to Medicines Index as a tool in its ESG research and engagement process with companies on this issue.